A new study published in February 2026 offers encouraging news for individuals with mild to moderate liver impairment who may require treatment with VV116 (Mindvy, JT001), an oral antiviral medication…
The post VV116 Pharmacokinetics & Safety in Mild/Moderate Hepatic Impairment – COVID-19 Study appeared first on News Directory 3.